TENX vs. VCNX, KTTA, SHPH, IBIO, BFRI, CVKD, PULM, HEPA, ASLN, and AIMD
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Vaccinex (VCNX), Pasithea Therapeutics (KTTA), Shuttle Pharmaceuticals (SHPH), iBio (IBIO), Biofrontera (BFRI), Cadrenal Therapeutics (CVKD), Pulmatrix (PULM), Hepion Pharmaceuticals (HEPA), ASLAN Pharmaceuticals (ASLN), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
Tenax Therapeutics (NASDAQ:TENX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.
Tenax Therapeutics received 17 more outperform votes than Vaccinex when rated by MarketBeat users. However, 60.00% of users gave Vaccinex an outperform vote while only 58.58% of users gave Tenax Therapeutics an outperform vote.
Tenax Therapeutics' return on equity of -89.73% beat Vaccinex's return on equity.
Tenax Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 1.9% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Tenax Therapeutics had 3 more articles in the media than Vaccinex. MarketBeat recorded 8 mentions for Tenax Therapeutics and 5 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.37 beat Tenax Therapeutics' score of -0.74 indicating that Vaccinex is being referred to more favorably in the news media.
Tenax Therapeutics has higher earnings, but lower revenue than Vaccinex.
Tenax Therapeutics currently has a consensus price target of $480.00, suggesting a potential upside of 13,424.94%. Given Tenax Therapeutics' higher possible upside, equities research analysts plainly believe Tenax Therapeutics is more favorable than Vaccinex.
Summary
Tenax Therapeutics beats Vaccinex on 8 of the 13 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
